TickerGuard
Buy Day today: Neutral (54) Mixed market breadth · no major macro event
SYRE

Spyre Therapeutics Inc.

Healthcare · Biotechnology

80.10$ -13.6% vs. previous close Closing price · As of: Oct 6, 2026

Statements

Balance Sheet

Spyre Therapeutics Inc. (SYRE) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 1,173 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios
Annual Quarterly
Amounts Change % Common size %
Last 12 Full history
Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet SYRE
Line item Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
72 67 61 67 61 56 50 80 71 78 129 117 100 83 65 173 156 162 164 147 129 110 83 107 92 71 52 244 207 342 488 436 421 608 570 539 505 778 764 1,173
72 66 60 66 60 55 49 79 70 77 127 110 93 75 54 162 144 150 151 134 118 99 73 97 82 62 44 240 206 342 487 436 421 608 570 539 505 778 764 1,173
50 48 17 27 13 13 11 21 15 22 86 25 25 19 13 66 54 90 80 35 25 15 15 37 39 35 35 235 91 189 228 45 72 89 48 82 65 86 97 162
68 64 58 63 56 50 43 72 65 75 124 106 89 72 49 158 140 146 127 129 112 93 67 89 74 56 38 235 204 339 485 426 414 603 565 527 486 757 741 1,145
1.6 1.2 1.0 1.2 2.5 3.1 3.4 4.3 2.4 – – – – – – – – – 22 – – 0.8 1.0 0.5 0.7 0.4 0.3 1.6 0.2 – – – – – – 3.5 3.6 – 4.6 –
– – – – – – – – – – – – – – – – – – – – – – 0.0 – – – – – – – – – – – – – – – – –
3.9 4.1 4.1 4.5 5.0 5.7 5.9 6.3 7.6 10 12 18 20 23 22 21 19 22 40 28 27 26 22 23 24 21 19 451 453 158 335 62 94 91 87 83 50 63 93 72
3.8 4.0 4.0 4.4 4.9 5.6 5.8 6.2 7.5 10 12 13 15 18 17 16 14 16 32 21 20 20 16 16 18 15 13 232 45 32 43 22 58 54 71 83 46 59 85 63
– – – – – – – – – – 0.3 0.3 0.3 0.4 0.3 0.2 0.3 0.3 0.3 0.4 0.4 0.4 0.5 0.5 0.6 0.6 0.6 4.3 – – – – – – – – – – – –
0.5 0.2 0.3 0.6 0.6 0.4 0.8 1.0 1.1 0.7 3.2 2.7 2.4 3.2 3.6 4.2 2.3 2.3 1.9 2.2 1.9 3.3 3.0 2.0 4.2 0.7 2.1 2.9 1.7 0.9 3.1 3.2 5.2 0.7 3.7 3.7 7.5 8.9 5.7 5.7
68 63 57 63 56 50 44 73 64 67 116 100 80 60 43 152 136 140 124 119 102 84 62 84 68 50 34 -207 -245 184 152 374 327 518 483 456 455 715 671 1,101
-40 -45 -52 -58 -66 -73 -81 -90 -102 -117 -134 -152 -174 -195 -214 -235 -253 -276 -294 -301 -321 -342 -366 -389 -407 -426 -444 -661 -701 -764 -808 -847 -916 -972 -1,017 -1,054 -1,065 -1,128 -1,197 -1,233
0.5 0.5 0.5 0.6 0.7 0.6 0.7 0.8 0.9 1.0 1.2 1.3 1.3 1.3 1.3 2.1 2.5 2.3 2.6 2.6 2.6 2.0 2.6 3.3 3.8 2.6 3.8 3.8 4.3 22 37 45 51 47 60 61 60 75 79 85

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?